Answers are grounded in this paper and cite their sources.
A generic miltefosine pharmaceutical product containing no active pharmaceutical ingredient for the treatment of visceral leishmaniasis emerged in Bangladesh for use in the national elimination programme. Poor-quality drugs for the treatment of this fatal neglected tropical disease are life-threatening for the vulnerable patients using them but also have a devastating impact on public health and elimination programmes targeting this disease. National drug regulators should take responsibility and ensure without any concessions that procured drugs for neglected tropical diseases, either innovator or generic, adhere to international standards for drug quality and safety.
No takes yet. Share an insight, caveat, or question.
Dorlo et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: